Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd46db19f76693118780d061d250cc83 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6801 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2017-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42f22395f833061e361cdfd467ba5812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb696c7d2aec8d650446c5a1528645cd |
publicationDate |
2022-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
RU-2766586-C2 |
titleOfInvention |
Pharmaceutical composition for treatment and/or prevention of malignant tumor |
abstract |
FIELD: biotechnology.SUBSTANCE: present invention relates to the field of biotechnology, specifically to a conjugate of an antibody specific to CAPRIN-1 protein or its antigen-binding fragment with an immune activator. The invention allows for obtaining a new conjugate of an anti-CAPRIN-1 antibody with immune activators, in particular with TL7/8 agonists – reziquimod or its derivatives, that has significantly stronger antitumor effect compared to immunoconjugates known from the technology level.EFFECT: invention can be used in medicinal practice as a drug in the treatment of malignant neoplasms expressing CAPRIN-1 protein on the surface of cell membrane.12 cl, 11 ex |
priorityDate |
2016-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |